Title: Clinical study on the expression of serum miR-202 and miR-34a and nosocomial infection in patients with primary liver cancer after TACE
Abstract:
To analyze the relationship between the expression of serum microRNA (miR) -202 and miR-34a and nosocomial infection after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer.
Methods: A total of 125 patients with primary liver cancer who underwent TACE in our hospital from February 2020 to August 2023 were selected. The clinical data of patients were collected, and the relative expression levels of serum miR-202 and miR-34a were measured before operation by real-time PCR. According to whether nosocomial infection occurred after TACE, the patients were divided into infection group and non-infection group. The relative expression levels of serum miR-202 and miR-34a and clinical data were compared between the two groups. Multivariate Logistic regression model was used to analyze the influencing factors of nosocomial infection after TACE for primary liver cancer. The receiver operating characteristic curve (ROC) was drawn to analyze the value of serum miR-202, miR-34a and their combination in predicting nosocomial infection.
Results: There were 18 cases of nosocomial infection in 125 cases of primary liver cancer, the incidence rate was 14.40% (18/125). The relative expression levels of serum miR-202 and miR-34a in the infected group were lower than those in the uninfected group (P<0.05). The proportion of patients aged ≥60 years old, combined with diabetes, ascites, no preventive use of antibiotics and intervention time ≥120min in the infected group was higher than that in the uninfected group, and the proportion of preventive use of antibiotics was lower than that in the uninfected group (P<0.05). Multivariate Logistic regression showed that the patients aged ≥60 years old, complicated with diabetes, complicated with ascites, and intervention time ≥120min were the risk factors for nosocomial infection in patients with primary liver cancer after TACE (OR>1, P<0.05), and the relative expression levels of serum miR-202 and miR-34a were the protective factor (OR<1, P<0.05). The ROC curve showed that the AUC (95%CI) of serum miR-202, miR-34a and their combination in predicting nosocomial infection after TACE in patients with primary liver cancer were 0.852(0.825-0.879), 0.737(0.686-0.787) and 0.909 (0.885-0.999), respectively.
Conclusion: The low serum expression of miR-202 and miR-34a in patients with nosocomial infection after TACE for primary liver cancer will increase the risk of nosocomial infection, and the combination of them can effectively predict the occurrence of nosocomial infection.
[Keywords] Primary liver cancer; miR-202; miR-34a; Hepatic arterial infusion chemotherapy and embolization; Hospital infection
